Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 342 (LINC00342)
- Target
- LINC00342
- Molecular classification
- Long non-coding RNA (lncRNA), Other (not protein, not a receptor, not an enzyme; intergenic transcript)
01
Overview
Long intergenic non-protein coding RNA 342 (LINC00342) is a long non-coding RNA transcript located on chromosome 2q11.1, not overlapping any protein-coding regions. It is upregulated in various cancers, including colorectal cancer and non-small cell lung cancer, and acts as an oncogene by promoting cancer cell proliferation, migration, invasion, and tumor growth. Mechanistically, it functions as a competitive endogenous RNA (ceRNA), binding miR-19a-3p and regulating the expression of aminopeptidase like 1 (NPEPL1). High expression of LINC00342 correlates with poor prognosis in several cancers. LINC00342 is emerging as a potential diagnostic and prognostic biomarker, though direct drug targeting has not yet reached clinical use.
- Other names
- Long intergenic non-coding RNA 342LINC00342HGNC:42470NCBI Gene:150759Ensembl:ENSG00000232931Previous symbol: NCRN
02
Mechanism of action
Antisense oligonucleotide-mediated knockdown (inhibits LINC00342 activity by degrading or blocking its RNA transcript). Small molecule inhibitors or RNAi (theoretical approaches to interrupt its function or expression).
03
Biological functions
Cell proliferation (promotes tumor cell growth in vitro and in vivo)Cell migration (facilitates metastatic phenotypes)Cell invasionGene expression regulation (participates in competitive endogenous RNA networks by sponging miRNAs, notably miR-19a-3p)Other (epigenetic regulation, ceRNA function)
04
Disease associations
Cancer (especially colorectal cancer and non-small cell lung cancer; acts as oncogene)Other: tumor progression, poor prognosis association in NSCLC and infantile hemangiomas
05
Safety considerations
Off-target effects (by virtue of being a non-coding RNA, targeting may affect other cellular RNAs)Unknown physiological roles outside cancer (possible risk of disrupting normal gene regulation if targeted in non-cancer cells)Delivery challenges (typical for lncRNA-targeted therapeutics; issues include cell- or tissue-specific targeting and stability)
06
Biomarkers
Upregulated LINC00342 expression in tumor tissue (potential diagnostic/prognostic biomarker in colorectal cancer and NSCLC)Correlated with poor clinical outcome
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 342 (LINC00342).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 342 (LINC00342).